Utilizing CYP2D6 and BACE1 Structure Complexes to Reduce Risk of Drug-Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors
Michael A. Brodney(Vertex Pharmaceuticals (United States)), Brian T. O’Neill(Pfizer (United States)), Aijia Yu(WuXi AppTec (China)), David Riddell(Eli Lilly (United States)), Kevin Parris, Luis Martinez-Alsina(Pfizer (United States)), Leanne M. Buzon(Pfizer (United States)), Kevin Ogilvie(Pfizer (United States)), Shawn D. Doran(Pfizer (United States)), Kevin Atchison(Merck & Co., Inc., Rahway, NJ, USA (United States)), John C. Murray(Pfizer (United States)), Ashley Robshaw(Pfizer (United States)), Karen D. B. Dutra, Peter Mikochik(Pfizer (United States)), Subas M. Sakya(Pfizer (United States)), Eric F. Johnson(Pfizer (United States)), Christopher R. Butler(Pfizer (United States)), Ricardo Lira(Pfizer (United States)), Elizabeth M. Beck(Pfizer (United States)), Ying Fan(Scripps Research Institute), Gabriela Barreiro(Pfizer (United States)), Bruce N. Rogers(Pfizer (United States)), Cathleen Gonzales
Unknown
January 1, 2015
Cited by 1
Related Papers
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k
ABC transporters: the power to change
|Nature Reviews Molecular Cell Biology|2009|1.4k
ApoE Promotes the Proteolytic Degradation of Aβ
|Neuron|2008|869
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
|Clinical Cancer Research|2007|776
Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor
|Journal of Medicinal Chemistry|2012|460